Skip to main content

BBS-Bioactive Bone Substitutes Plc: Animal test results completed contributing on their part to submitting the CE marking application

Written by Customer Service on . Posted in Public Companies.

Company Release, Inside Information, September 7th 2021, at 5:45 p.m.

The management of BBS-Bioactive Bone Substitutes  Plc has today September 7, 2021 approved the final report on the results of the animal test (sheep).

The results of the experiment confirm the functionality of Artebone ® Paste, which contains reindeer bone protein extract, and make it possible for the company to respond positively to the demands made by the authorities. According to the final report, Artebone®  Paste causes bone to heal faster than the alternatives (ceramic and extract alone).

CEO Ilkka Kangasniemi:
“The results of the animal testing were in line with our expectations and are clinically significant. Positive results are an important step forward for our company and significantly reduce the risks associated with obtaining the CE marking. We will provide further information regarding the application schedule by the end of September.

The animal test was carried out at the request of the authorities to provide supplementary documentation for the CE marking application. The experiment was aimed at demonstrating that Artebone®  Paste can be classified as a medical device and has an acceptable efficacy.

The company has described the application process for the CE marking and as well as the related delays in its half-year financial report published on 25 August 2021.

Oulu, September 7th, 2021

For more information:
CEO Ilkka Kangasniemi
Tel: +358 40 7080 307
Ilkka.kangasniemi@bbs-artebone.fi

Certified Adviser:
Nordic Certified Adviser AB,
+46 70 551 67 29, info@certifiedadviser.se

DISTRIBUTION:
Nasdaq Helsinki Oy
Nasdaq Stockholm AB
Key media

www.bbs-artebone.fi

This is information that BBS-Bioactive Bone Substitutes Plc is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above on 7th September 2021 at 5:45 pm (UTC+2:00).

BBS-Bioactive Bone Substitutes Plc is the health technology company operating since 2003. Before that there was a background of seven years of product development in the University of Oulu. We have developed a new product for healing of difficult bone fractures and for solving the problems in bone healing. Our mission is to offer new generation medicinal products for the orthopedic surgery. The research and development in the field of medicine requires perseverance and courage to develop new things. We have over 20 years of expertise in this. Our operations are characterized by top expertise, innovativeness and dedicated and committed employees. The ARTEBONE ®product is ready and the application process for the CE-mark has been initiated. BBS is the company having its headquarters in Oulu. We have our own production plant located in Reisjärvi and it is approved by FIMEA. More information: www.bbs-artebone.fi

BBS-Bioactive Bone Substitutes Plc shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.